TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17445222

Group type: EXPERIMENTAL
Intervention: HLA class I and II and cytokine gene polymorphisms in healthy elderly individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokine gene polymorphisms in healthy elderly individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inheritance of extended haplotypes in families with longevity members
Number of subjects: 0

Group type: COMPARATOR
Intervention: HLA class I and II and cytokine gene polymorphisms in families with longevity members
Number of subjects: 0
Study: 14739015

Group type: EXPERIMENTAL
Intervention: Cross-modal integration of object information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-modal integration of object information
Number of subjects: 0
Study: 12390820

Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine for 2 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 99
Study: 9661591

Group type: EXPERIMENTAL
Intervention: VDR polymorphic alleles (b, a, T)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: baT haplotype
Number of subjects: 42
Study: 7779153

Group type: EXPERIMENTAL
Intervention: Cimetidine with Brand 1 of praziquantel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine with Brand 2 (Distocide) of praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brand 1 of praziquantel alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brand 2 of praziquantel alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brand 2 plus cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate or glucose with either Brand 1 or Brand 2
Number of subjects: 0
Study: 1972139

Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 429174

Group type: EXPERIMENTAL
Intervention: Irrigation of the wound with saline and antibiotics
Number of subjects: 162

Group type: COMPARATOR
Intervention: Irrigation of the wound with saline alone
Number of subjects: 162

Group type: COMPARATOR
Intervention: Non-irrigated group
Number of subjects: 162
Study: 31880167

Group type: EXPERIMENTAL
Intervention: CFT-based self-help intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Waitlist control group (usual medical care)
Number of subjects: 176
Study: 30972871

Group type: EXPERIMENTAL
Intervention: Dr. Wolff Gel (test gel)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Biotene (control gel)
Number of subjects: 32
Study: 27762647

Group type: EXPERIMENTAL
Intervention: Salicylic acid peels (10%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phototherapy (blue LED and red laser lights)
Number of subjects: 0
Study: 26143483

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients underwent resting-state fMRI and functional connectivity density mapping (FCD).
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis in schizophrenia patients.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy controls underwent resting-state fMRI and functional connectivity density mapping (FCD).
Number of subjects: 29
Study: 23841872

Group type: EXPERIMENTAL
Intervention: Postoperative seizure control at 12 months after surgery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BCL2A1 as a biomarker
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Increased expression of anti-apoptotic genes
Number of subjects: 54
Study: 20653433

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash with an antidiscoloration system (ADS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine mouthwash (control group)
Number of subjects: 15
Study: 19858419

Group type: EXPERIMENTAL
Intervention: CRT on (active therapy)
Number of subjects: 610

Group type: COMPARATOR
Intervention: CRT off (control)
Number of subjects: 610
Study: 17130505

Group type: EXPERIMENTAL
Intervention: High-sucrose diet (25% of total energy intake)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low-sucrose diet (10% of total energy intake)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 13
Study: 15448429

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cow milk challenge during esophageal pH monitoring
Number of subjects: 42
Study: 11376649

Group type: EXPERIMENTAL
Intervention: Loperamide (4 mg) and Acetaminophen (500 mg) before vaginal misoprostol (800 mcg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol (800 mcg) without prophylactic medication
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Loperamide and Acetaminophen
Number of subjects: 200

Group type: COMPARATOR
Intervention: Misoprostol without prophylactic medication
Number of subjects: 200
Study: 9151927

Group type: EXPERIMENTAL
Intervention: YNK-01 at 200 mg/d
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: YNK-01 at 300 mg/d
Number of subjects: 32
Study: 7476236

Group type: EXPERIMENTAL
Intervention: Immunotherapy with parasite derived antigen (94‐67 KD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Antimonial therapy
Number of subjects: 25
Study: 2525330

Group type: EXPERIMENTAL
Intervention: Nicorandil (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem (low-dose 60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem (high-dose 120 mg)
Number of subjects: 12
Study: 31463484

Group type: EXPERIMENTAL
Intervention: Modified vertical internal mattress sutures
Number of subjects: 48

Group type: COMPARATOR
Intervention: Simple loop interrupted sutures
Number of subjects: 48
Study: 28095801

Group type: EXPERIMENTAL
Intervention: Small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron & folic acid (IFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SQ‐LNS
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMN
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFA
Number of subjects: 0
Study: 26248034

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications (diet and exercise) and intensive glycemic control
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sildenafil citrate® 100 mg for 2-3 times per week in addition to intensive glycemic control
Number of subjects: 83
Study: 23868156

Group type: EXPERIMENTAL
Intervention: Automated WM lesion segmentation using the Lesion Segmentation Toolbox
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Automated WM lesion segmentation using the Lesion Segmentation Toolbox at k = 0.25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subjective WM lesion segmentation
Number of subjects: 50
Study: 21269294

Group type: EXPERIMENTAL
Intervention: Short-term ketogenic diet (8 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Long-term ketogenic diet (> 2 years)
Number of subjects: 40
Study: 19756419

Group type: EXPERIMENTAL
Intervention: Continuous 24-h infusion of 100 mg/kg per day ceftazidime
Number of subjects: 56

Group type: COMPARATOR
Intervention: Thrice-daily dosing of 200 mg/kg per day ceftazidime
Number of subjects: 56
Study: 16954547

Group type: EXPERIMENTAL
Intervention: No evidence of diabetes
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diabetes mellitus
Number of subjects: 22
Study: 15063387

Group type: EXPERIMENTAL
Intervention: 8 mg lycopene/day (Group A)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4 mg lycopene/day (Group B)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 58
Study: 11772139

Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha-2a (40 kD) 180 microg/week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon-alpha-2a (40 kD)
Number of subjects: 0
Study: 9228499

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 8233297

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342

Group type: COMPARATOR
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study: 2423799

Group type: EXPERIMENTAL
Intervention: Indoramin added to HCTZ
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Prazosin added to HCTZ
Number of subjects: 209

Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 209
Study: 29530495

Group type: EXPERIMENTAL
Intervention: GA-driven intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 27647710

Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 158
Study: 23686394

Group type: EXPERIMENTAL
Intervention: Horizon stabilization software
Number of subjects: 18

Group type: COMPARATOR
Intervention: No horizon stabilization
Number of subjects: 18
Study: 22496538

Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program (3 times/week; three sets, six to eight repetitions at 75%-80% of one-repetition maximum)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 12-week resistance exercise program
Number of subjects: 237
Study: 20888262

Group type: COMPARATOR
Intervention: Backpack repair
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dual Row repair
Number of subjects: 10
Study: 17914351

Group type: EXPERIMENTAL
Intervention: Biocompatible dialysis solutions (B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard dialysis solutions (S)
Number of subjects: 93
Study: 16157429

Group type: EXPERIMENTAL
Intervention: Inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 303
Study: 14566313

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin ophthalmic solution
Number of subjects: 167

Group type: COMPARATOR
Intervention: 0.3% ofloxacin
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 10751698

Group type: EXPERIMENTAL
Intervention: Burn injury group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fracture group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non ill/injured group
Number of subjects: 40
Study: 8981915

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (r-hGH; 2.0 IU/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1536016

Group type: EXPERIMENTAL
Intervention: 0.5 ml (2.0 mg) of chymopapain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.0 ml (8.0 mg) of chymopapain
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5 ml (2.0 mg) of chymopapain and 2.0 ml (8.0 mg) of chymopapain
Number of subjects: 30
Study: 6342219

Group type: EXPERIMENTAL
Intervention: Low maintenance dose of prednisone (30 mg/day) and antilymphocyte globulin (ALG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High maintenance doses of prednisone (2 mg/kg/day with tapering) and intravenous methylprednisolone (IVMP)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low maintenance dose of prednisone (30 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High maintenance doses of prednisone (2 mg/kg/day with tapering)
Number of subjects: 23
Study: 31971914

Group type: EXPERIMENTAL
Intervention: Pressure on P6 (Neiguan) point
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pressure on KID21 (Youmen) point
Number of subjects: 82

Group type: COMPARATOR
Intervention: Both P6 and KID21 pressure groups
Number of subjects: 82
Study: 31138134

Group type: EXPERIMENTAL
Intervention: Voriconazole (with and without anidulafungin)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (non-confirmed invasive aspergillosis)
Number of subjects: 395
Study: 29228935

Group type: EXPERIMENTAL
Intervention: Nebulized 2.0% morphine
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0.9% NaCl (control)
Number of subjects: 11
Study: 25307409

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type-A (BoNT‐A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 24151217

Group type: EXPERIMENTAL
Intervention: Recording 20-26 words per day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Recording 27-33 words per day
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Recording ≥34 words per day
Number of subjects: 549

Group type: COMPARATOR
Intervention: Recording <20 words per day
Number of subjects: 549
Study: 22866290

Group type: EXPERIMENTAL
Intervention: Free gingival grafts (FGG group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vestibuloplasty (VP group)
Number of subjects: 64
Study: 19407955

Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with composite salvia injection (CSI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 150
Study: 17406813

Group type: EXPERIMENTAL
Intervention: Aspartame-based liquids
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sucrose-based liquids
Number of subjects: 51
Study: 15107411

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 16
Study: 11179128

Group type: EXPERIMENTAL
Intervention: NAECC criteria
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: LISS criteria
Number of subjects: 118

Group type: COMPARATOR
Intervention: NAECC vs LISS
Number of subjects: 118
Study: 9568649

Group type: EXPERIMENTAL
Intervention: Intraoperative abdominal cavity culture obtained in group A (30.1%)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Intraoperative abdominal cavity culture obtained in group B (67.1%)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Single antibiotic agent treatment in group A
Number of subjects: 499

Group type: COMPARATOR
Intervention: Triple-agent antibiotics in group B
Number of subjects: 499
Study: 8041524

Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of spatula and Cytobrush
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of spatula and swab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervex brush alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: All methods
Number of subjects: 0
Study: 3045271

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study: 31160252

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28938473

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nonexercising control subjects
Number of subjects: 32
Study: 26151244

Group type: EXPERIMENTAL
Intervention: Whey associated with dodder seed extract
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23973504

Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma (ACP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 54
Study: 21595877

Group type: COMPARATOR
Intervention: Systematic program for increasing influenza vaccine uptake among HCWs
Number of subjects: 0
Study: 19084800

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation (CPVA, group 1, n = 47)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI, group 2, n = 48)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Hybrid strategy combining CFAE ablation and PVAI (CFAE + PVAI, group 3, n = 49)
Number of subjects: 144
Study: 17154782

Group type: EXPERIMENTAL
Intervention: Object substitution masking (OSM)
Number of subjects: 0
Study: 12701008

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclipping for gastric body Dieulafoy lesions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Endoscopic epinephrine injection therapy for gastric body Dieulafoy lesions
Number of subjects: 32
Study: 10764298

Group type: EXPERIMENTAL
Intervention: Nadroparin (0.4 ml, 3,800 AXa IU or 0.6 ml, 5,700 AXa IU)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 223
Study: 9363412

Group type: EXPERIMENTAL
Intervention: Lofexidine (maximum daily dose: 1.6 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine (maximum daily dose: 0.6 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lofexidine and Clonidine
Number of subjects: 80
Study: 1582811

Group type: EXPERIMENTAL
Intervention: New Aniseikonia Test (NAT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Space Eikonometer
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Computer-video simulation of NAT
Number of subjects: 19
Study: 3157936

Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) performed initially in group I patients.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional examinations (including 20 invasive) performed in a definite order in group II patients.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) performed in group I patients.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional examinations performed in group II patients.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Abdominal computerized tomography (CT) if performed early in all patients.
Number of subjects: 36
Study: 30736383

Group type: EXPERIMENTAL
Intervention: Mangiferin + Luteolin (PHE: 50 mg/day; MLE: 140 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mangiferin + Luteolin (PHE: 100 mg/day; MLE: 420 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28920491

Group type: EXPERIMENTAL
Intervention: Prescriber communication behaviors (facilitation, rapport, procedural, psychosocial, biomedical, total utterances)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Ratio of prescriber to consumer utterances
Number of subjects: 175
Study: 26775275

Group type: EXPERIMENTAL
Intervention: Planned rotational atherectomy (RA)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Provisional rotational atherectomy (RA)
Number of subjects: 667
Study: 23902933

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Orthopedic care (OC)
Number of subjects: 397
Study: 22648467

Group type: EXPERIMENTAL
Intervention: Resistance Training Men (RTM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resistance Training Women (RTW)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group Men (CGM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group Women (CGW)
Number of subjects: 50
Study: 19321507

Group type: EXPERIMENTAL
Intervention: Volume Controlled Ventilation (VCV)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Pressure Limited Ventilation (PLV)
Number of subjects: 109
Study: 16732060

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (ICRT) with 17 Gy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Intracoronary radiation therapy (ICRT) with 14 Gy
Number of subjects: 336
Study: 12687820

Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers during CAEP test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers during Harbor test
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control group during CAEP test
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control group during Harbor test
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dual sensor DDDR pacemakers
Number of subjects: 25
Study: 10737151

Group type: EXPERIMENTAL
Intervention: Two active bars/day
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: One active bar/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo groups (one active and one placebo bar, and two placebo bars per day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: General and emotional/social functioning components of SF-36
Number of subjects: 41
Study: 9372298

Group type: EXPERIMENTAL
Intervention: Left hand in left space
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right hand in right space
Number of subjects: 0
Study: 1351673

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) with Triazolam (0.250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg) with Zopiclone (7.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with Triazolam (0.250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with Zopiclone (7.5 mg)
Number of subjects: 0
Study: 3985085

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic)
Number of subjects: 11
Study: 31493783

Group type: EXPERIMENTAL
Intervention: Smartphone application (MEmind) for ecological momentary assessment (EMA) data capture related to sleep, appetite, and suicide ideations.
Number of subjects: 0
Study: 30469433

Group type: EXPERIMENTAL
Intervention: hypothermic histidine‐tryptophan‐ketoglutarate (HTK) solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: normothermic oxygenated blood
Number of subjects: 90

Group type: COMPARATOR
Intervention: standard CPB with no pulmonary perfusion
Number of subjects: 90
Study: 27228959

Group type: EXPERIMENTAL
Intervention: Flexible fibrescope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentax Airway Scope
Number of subjects: 40
Study: 24849441

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI (98 lesions)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI (101 lesions)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard medical treatment (medication group, 94 lesions)
Number of subjects: 226
Study: 22595272

Group type: EXPERIMENTAL
Intervention: Rapid diagnostic tests (RDTs), artemether-lumefantrine (AL), amoxicillin
Number of subjects: 1017
Study: 19019358

Group type: EXPERIMENTAL
Intervention: Metformin (1 g two times per day, n = 36)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral contraceptive pill (OCP) (35 microg ethinyl E(2)‐2 mg cyproterone acetate, n = 30)
Number of subjects: 66